Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
siNRP-1
- Development stage
- Preclinical
- Lead developer
- University of Toronto
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
siNRP-1 is a small interfering RNA (siRNA) designed to silence the expression of Neuropilin-1 (NRP-1). NRP-1 is a transmembrane glycoprotein that serves as a co-receptor for various ligands, including vascular endothelial growth factor (VEGF) and transforming growth factor beta 1 (TGFβ1), and is implicated in tumor progression, epithelial-mesenchymal transition (EMT), and autophagy. In preclinical models of pancreatic ductal adenocarcinoma (PDAC), siNRP-1 has been shown to reverse chemoresistance to gemcitabine by suppressing TGFβ1-induced EMT and inhibiting autophagy flux. By reducing NRP-1 protein levels, the treatment promotes apoptosis and restores sensitivity to chemotherapy in resistant pancreatic cancer cell lines.
- Other names
- neuropilin-1 siRNAneuropilin1 siRNAneuropilin 1 siRNANRP-1 siRNANRP1 siRNANRP 1 siRNA
02
Targets
NRP1 (Neuropilin-1)
Beyond the preview
Go deeper on siNRP-1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on siNRP-1.